Group 1 - Nvidia will invest $1 billion with Eli Lilly over the next five years to establish an AI drug laboratory, focusing on robotics and physical AI to accelerate medical discoveries and production [1] - Rongchang Bio announced a licensing agreement with AbbVie for RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [1] - OpenAI data indicates over 230 million weekly inquiries related to health and wellness, highlighting the significant demand in the healthcare market [1] Group 2 - The STAR Market 100 Index (000698) shows mixed performance, with Rongchang Bio leading gains at 19.99%, while the STAR 100 ETF (588220) has a recent price of 1.54 yuan and a turnover rate of 9.21% [2] - The STAR 100 ETF has reached a new high in scale at 10.315 billion yuan, with an average daily turnover of 467 million yuan over the past month [2] - The top ten weighted stocks in the STAR Market 100 Index account for 26.21% of the index, including companies like Huahong Semiconductor and BeiGene [2]
科创100ETF基金(588220)日均成交4.67亿，AI应用领涨市场
Xin Lang Cai Jing·2026-01-13 05:48